- Home
- LLY
as 12-20-2024 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 755.9B | IPO Year: | N/A |
| Target Price: | $963.64 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 9.25 | EPS Growth: | 67.52 |
| 52 Week Low/High: | $567.42 - $972.53 | Next Earning Date: | 02-06-2025 |
| Revenue: | $40,863,300,000 | Revenue Growth: | 27.41% |
| Revenue Growth (this year): | 34.95% | Revenue Growth (next year): | 28.48% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zakrowski Donald A | LLY | SVP, Finance, & CAO | Nov 8 '24 | Sell | $803.38 | 900 | $723,042.00 | 5,480 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Motley Fool
5 hours ago
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves
TipRanks
6 hours ago
Novo obesity data positive for Eli Lilly and Amgen, says UBS
TipRanks
6 hours ago
Weight loss seen with Novo’s CagriSema weaker than expected, says BofA
Motley Fool
9 hours ago
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
The Wall Street Journal
17 hours ago
Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients
Barrons.com
19 hours ago
Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.
Investor's Business Daily
19 hours ago
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
MT Newswires
20 hours ago
Eli Lilly Gets FDA Approval for Zepbound to Treat Sleep Apnea, Obesity
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.